Nicotine Science and Policy

What is inside a nicotine pouch matters because consumers deserve to understand the products they use. Beyond nicotine, pouches typically contain plant-based fibres, pH adjusters, flavourings, sweeteners and stabilisers that affect how the product feels, tastes and delivers nicotine. That does not make them risk-free, but it does make them very different from cigarettes, where burning tobacco creates thousands of toxic chemicals. Better public health communication should explain product contents clearly, rather than leaving nicotine pouches to be judged by suspicion alone.

The Royal College of Physicians has historically helped move the UK debate towards harm reduction, which makes any drift back into risk confusion especially significant. Clinical leadership should make the hierarchy clear: smoking remains the central danger, while smoke-free nicotine products can offer adults a less harmful route away from combustion. Overstating uncertainty or treating alternatives too cautiously may leave smokers with the impression that switching offers little benefit. Medical authority should reduce confusion, not reinforce the conditions that keep cigarettes in use.

Estonia’s smoking rate falling by more than a quarter while vaping more than triples is a trend policymakers should examine closely. It suggests a shift in nicotine use that may be moving some adults away from combustible tobacco rather than simply adding new use. The important question is not whether vaping increased in isolation, but what happened to smoking at the same time. Regulation should protect young people and maintain product standards, while recognising that movement away from cigarettes can be a meaningful public health gain.

The EU’s direction on nicotine bans should be judged by what it leaves behind. Removing smoke-free alternatives from legal markets does not remove nicotine use; it can leave adult smokers with fewer routes away from cigarettes and give illicit suppliers more room to grow. That is the risk of policy built around exclusion rather than comparison. A European tobacco strategy should distinguish between products, protect young people through enforcement, and keep lower-risk options available for those still exposed to combustion.

The FDA’s tobacco centre reworking its product review process matters because the current system has struggled to keep pace with the market it is supposed to regulate. Slow, uncertain pathways can leave responsible products waiting while cigarettes remain widely available and unapproved alternatives continue to circulate. A better review model should be faster without becoming weaker: clear standards, transparent decisions and evidence assessed according to relative risk. The goal should be a legal market where safer nicotine products are reviewed in time to help smokers move away from combustion.